X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-10-07 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $32.06 | -3,809 | 201,532 | -2% | -$122,117 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $32.06 | -1,327 | 175,218 | -1% | -$42,544 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $32.06 | -2,241 | 217,060 | -1% | -$71,846 | ||||||
| M | 2026-10-08 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $94.07 | -63,209 | 39,218,111 | 0% | -$5,945,855 | |||||
2026-10-08 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.90 | +5,000 | 15,000 | +50% | +$44,500 | ||||||
| DM | 2026-10-06 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $110.18 | -60,000 | 767,780 | -7% | -$6,610,501 | |||||
| DM | 2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $26.60 | -35,643 | 377,802 | -9% | -$948,223 | |||||
2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $30.00 | -6,444 | 389,350 | -2% | -$193,320 | ||||||
| D | 2026-10-06 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $60.04 | -1,990 | 94,784 | -2% | -$119,481 | |||||
2026-10-07 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $18.10 | -48,199 | 1,358,204 | -3% | -$872,402 | ||||||
2026-10-06 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.59 | -17,717 | 105,134 | -14% | -$329,322 | ||||||
2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.84 | -50,000 | 6,108,287 | -1% | -$242,000 | ||||||
| D | 2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Hershberg Robert | Dir | S - Sale+OE | $5.00 | -25,000 | 162,156 | -13% | -$125,000 | |||||
2026-10-07 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $95.86 | -24,000 | 39,281,320 | 0% | -$2,300,633 | ||||||
2026-10-05 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $12.92 | -58,333 | 709,153 | -8% | -$753,937 | ||||||
2026-10-05 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale | $15.00 | -2,403 | 49,448 | -5% | -$36,045 | ||||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $86.74 | -18,000 | 145,435 | -11% | -$1,561,320 | |||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $86.74 | -19,000 | 27,860 | -41% | -$1,648,060 | |||||
| D | 2026-10-05 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $202.15 | -4,548 | 562,760 | -1% | -$919,374 | |||||
2026-10-06 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $7.20 | -23,463 | 1,519,606 | -2% | -$168,880 | ||||||
| M | 2026-10-05 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.64 | +10,000 | 10,000 | New | +$86,350 | |||||
2026-10-06 | AGMB | Agomab Therapeutics Nv | Kemula Pierre Thadee Victor | CFO | P - Purchase | $8.59 | +10,000 | 10,000 | New | +$85,940 | ||||||
| M | 2026-10-05 | AGMB | Agomab Therapeutics Nv | Knotnerus Tim Jasper | CEO | P - Purchase | $8.58 | +11,000 | 56,217 | +24% | +$94,380 | |||||
2026-10-06 | MGTX | Meiragtx Holdings Plc | Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY | S - Sale | $10.64 | -27,659 | 613,187 | -4% | -$294,292 | ||||||
2026-10-05 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $10.75 | -25,000 | 2,777,788 | -1% | -$268,760 | ||||||
| D | 2026-10-02 | IBRX | Immunitybio, Inc. | Cohen Cheryl | Dir | S - Sale+OE | $10.50 | -81,056 | 100,309 | -45% | -$851,088 | |||||
2026-10-02 | PTHS | Pelthos Therapeutics Inc. | Greenleaf Peter | Dir | S - Sale | $21.17 | -797 | 23,087 | -3% | -$16,872 | ||||||
2026-10-02 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Dir | S - Sale | $20.72 | -558 | 202,556 | 0% | -$11,560 | ||||||
2026-10-02 | PTHS | Pelthos Therapeutics Inc. | Pauls Matthew | Dir | S - Sale | $21.00 | -786 | 13,578 | -5% | -$16,506 | ||||||
| M | 2026-10-05 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $97.14 | -93,000 | 39,305,320 | 0% | -$9,033,642 | |||||
| D | 2026-10-05 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $187.29 | -5,535 | 45,788 | -11% | -$1,036,654 | |||||
2026-10-05 | GLUE | Monte Rosa Therapeutics, Inc. | Bowen Matthew | Principal Accounting Officer | S - Sale | $10.56 | -13 | 25,891 | 0% | -$137 | ||||||
2026-10-05 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $6.84 | -10,340 | 312,744 | -3% | -$70,697 | ||||||
2026-10-05 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $6.84 | -8,370 | 366,159 | -2% | -$57,227 | ||||||
2026-10-05 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $6.84 | -1,099 | 169,848 | -1% | -$7,514 | ||||||
2026-10-05 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $6.84 | -61,696 | 1,543,069 | -4% | -$421,828 | ||||||
2026-10-01 | GRML | Greenland Mines Ltd | El-Dada Riad Hussein | Former Director | S - Sale | $9.35 | -3,500 | 0 | -100% | -$32,727 | ||||||
| DM | 2026-10-01 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $28.46 | -35,643 | 377,802 | -9% | -$1,014,329 | |||||
| D | 2026-10-01 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $28.28 | -26,792 | 223,367 | -11% | -$757,697 | |||||
| D | 2026-10-02 | IMVT | Immunovant, Inc. | Venker Eric | CEO | S - Sale+OE | $34.11 | -3,506 | 257,075 | -1% | -$119,590 | |||||
| M | 2026-10-01 | PALI | Palisade Bio, Inc. | Williams Donald Allen | Dir | P - Purchase | $1.44 | +20,000 | 1,593,294 | +1% | +$28,800 | |||||
2026-10-02 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $188.88 | -8,057 | 100,576 | -7% | -$1,521,838 | ||||||
2026-10-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $188.88 | -10,088 | 106,632 | -9% | -$1,905,462 | ||||||
2026-10-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $188.88 | -25,714 | 185,088 | -12% | -$4,856,963 | ||||||
| DM | 2026-10-01 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $189.04 | -46,391 | 567,308 | -8% | -$8,769,799 | |||||
2026-10-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $188.88 | -9,514 | 63,789 | -13% | -$1,797,042 | ||||||
2026-10-02 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $188.88 | -1,482 | 42,917 | -3% | -$279,926 | ||||||
2026-10-01 | XFOR | X4 Pharmaceuticals, Inc | Kirske David | CFO | S - Sale | $2.86 | -11,767 | 155,983 | -7% | -$33,658 | ||||||
2026-09-30 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale | $23.04 | -536 | 54,305 | -1% | -$12,349 | ||||||
2026-10-01 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $147.90 | -15,000 | 566,683 | -3% | -$2,218,508 | ||||||
2026-10-01 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $108.54 | -5,230 | 53,609 | -9% | -$567,661 | ||||||
| M | 2026-10-01 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $97.09 | -34,000 | 39,398,320 | 0% | -$3,301,069 | |||||
2026-10-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $27.02 | -34,501 | 234,367 | -13% | -$932,260 | ||||||
| D | 2026-10-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $26.93 | -16,141 | 0 | -100% | -$434,743 | |||||
| D | 2026-10-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $56.67 | -2,250 | 145,435 | -2% | -$127,513 | |||||
2026-10-01 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.69 | +19,050 | 3,322,954 | +1% | +$165,634 | ||||||
2026-10-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.41 | -187 | 50,984 | 0% | -$4,565 | ||||||
2026-10-01 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $0.92 | +20,000 | 420,000 | +5% | +$18,400 | ||||||
| D | 2026-09-29 | RVMD | Revolution Medicines, Inc. | Sandler Alan B. | Chief Development Officer | S - Sale+OE | $202.14 | -6,309 | 52,559 | -11% | -$1,275,294 | |||||
| D | 2026-10-01 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $113.80 | -30,000 | 666,568 | -4% | -$3,413,917 | |||||
2026-09-29 | SLBT | Sl Science Holding Ltd | Wang Ching-Dong | CEO, 10% | P - Purchase | $2,272,650.00 | +4,545,306 | 333,832,129 | +1% | +$2,147,483,647 | ||||||
| D | 2026-09-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $27.06 | -7,500 | 32,316 | -19% | -$202,921 | |||||
2026-09-29 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.03 | +1,000 | 384,885 | 0% | +$1,030 | ||||||
| M | 2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $88.59 | +715,592 | 20,191,214 | +4% | +$63,397,609 | |||||
2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $83.58 | +418,323 | 19,515,907 | +2% | +$34,963,077 | ||||||
| M | 2026-09-29 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $98.19 | -66,000 | 39,432,320 | 0% | -$6,480,659 | |||||
2026-09-28 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $72.57 | +807,840 | 19,121,134 | +4% | +$58,625,708 | ||||||
2026-09-28 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $6.00 | +1,000 | 41,478 | +2% | +$6,000 | ||||||
2026-09-25 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | SVP, GC | S - Sale | $207.32 | -765 | 51,776 | -1% | -$158,600 | ||||||
2026-09-25 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $6.27 | +1,135 | 45,481 | +3% | +$7,116 | ||||||
2026-09-25 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $6.28 | +2,609 | 47,492 | +6% | +$16,385 | ||||||
| M | 2026-09-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.53 | +31,763 | 3,303,904 | +1% | +$270,800 | |||||
| DM | 2026-09-24 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $200.46 | -3,708 | 39,765 | -9% | -$743,285 | |||||
| M | 2026-09-25 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $99.88 | +10,000 | 960,413 | +1% | +$998,784 | |||||
| M | 2026-09-25 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $98.57 | -61,000 | 39,498,320 | 0% | -$6,012,500 | |||||
| D | 2026-09-24 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $190.00 | -12,946 | 48,369 | -21% | -$2,459,740 | |||||
2026-09-23 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $36.36 | -2,846 | 176,545 | -2% | -$103,481 | ||||||
| D | 2026-09-24 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $177.38 | -5,203 | 613,699 | -1% | -$922,907 | |||||
2026-09-24 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $1.14 | +2,500 | 400,000 | +1% | +$2,850 | ||||||
| D | 2026-09-22 | RVMD | Revolution Medicines, Inc. | Anderson Elizabeth M | Dir | S - Sale+OE | $193.04 | -10,143 | 46,323 | -18% | -$1,958,016 | |||||
| D | 2026-09-22 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $60.24 | -10,400 | 94,784 | -10% | -$626,460 | |||||
2026-09-22 | ENGN | Engene Therapeutics Inc. | Grossman William | Interim Chief Medical Officer | P - Purchase | $1.97 | +5,102 | 5,102 | New | +$10,051 | ||||||
| M | 2026-09-23 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $99.17 | -69,000 | 39,559,320 | 0% | -$6,842,742 | |||||
2026-09-23 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.05 | +1,900 | 383,885 | 0% | +$1,995 | ||||||
| D | 2026-09-21 | ETRA | Electra Therapeutics, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $15.00 | +1,333,333 | 1,758,279 | +314% | +$19,999,995 | |||||
| D | 2026-09-21 | ETRA | Electra Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $15.00 | +1,333,333 | 1,758,279 | +314% | +$19,999,995 | |||||
2026-09-23 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $100.00 | +5,000 | 1,074,046 | 0% | +$500,000 | ||||||
2026-09-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $165.49 | -348 | 73,303 | 0% | -$57,591 | ||||||
2026-09-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $165.49 | -294 | 116,720 | 0% | -$48,654 | ||||||
| D | 2026-09-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $165.49 | -1,687 | 618,902 | 0% | -$279,183 | |||||
| D | 2026-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $13.65 | -1,635 | 8,617 | -16% | -$22,318 | |||||
2026-09-18 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $196.94 | -1,764 | 40,352 | -4% | -$347,402 | ||||||
| M | 2026-09-21 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $99.50 | -79,000 | 39,628,320 | 0% | -$7,860,757 | |||||
| D | 2026-09-21 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale+OE | $180.00 | -5,426 | 48,369 | -10% | -$976,680 | |||||
| D | 2026-09-17 | CRSP | Crispr Therapeutics AG | Behbahani Ali | Dir | S - Sale+OE | $57.09 | -13,679 | 16,666 | -45% | -$780,935 | |||||
| D | 2026-09-17 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $157.99 | -356,546 | 620,589 | -36% | -$56,330,724 | |||||
| D | 2026-09-16 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $28.06 | -115,406 | 223,367 | -34% | -$3,238,004 | |||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Sandler Alan B. | Chief Development Officer | S - Sale | $199.24 | -341 | 52,868 | -1% | -$67,941 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $199.24 | -1,774 | 42,116 | -4% | -$353,449 | ||||||
2026-09-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $199.24 | -5,569 | 286,307 | -2% | -$1,109,554 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |